中新健康丨国家药监局批准马来酸美凡厄替尼片上市

Core Viewpoint - The National Medical Products Administration of China has approved the launch of the innovative drug Mevanertinib (brand name: Maiyidong), providing a new treatment option for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 21 (L858R) substitution mutations [1] Group 1: Drug Approval - The drug Mevanertinib is classified as a Class 1 innovative drug [1] - It is developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd [1] - The approval is significant as it offers a first-line treatment option for a specific patient population [1]